Premium
Pharmacokinetics of cyclophosphamide in patients with systemic necrotizing angiitis
Author(s) -
Belfayol L.,
Guillevin L.,
Louchahi K.,
Perrin P.,
Cherrier P.,
Lortholary O.,
Bosio AM,
Fauvelle F.
Publication year - 1994
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/j.1472-8206.1994.tb00826.x
Subject(s) - cyclophosphamide , pharmacokinetics , medicine , volume of distribution , concomitant , prednisone , chemotherapy , gastroenterology , urology , pharmacology
Summary— Cyclophosphamide pharmacokinetics were investigated following administration to patients with systemic necrotizing angiitis. Ten patients (eight women and two men) received cyclophosphamide as a 1‐h‐rate‐constant intravenous infusion at doses ranging from 600 to 1200 mg. All patients received concomitant oral prednisone (1 mg/kg/d). Blood samples were collected at the end of drug infusion and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h later. Serum cyclophosphamide concentrations were assayed by high pressure liquid chromatography. The peak serum cyclophosphamide levels ranged from 15.7 to 29.4 mg/L. The mean cyclophosphamide elimination half‐life was 6.2 ± 1.3 h (mean ± SD). The mean apparent volume of distribution and mean total plasma clearance were, respectively, 0.75 ± 0.22 L/kg (mean ± SD) and 83 ± 22 mL/min (mean ± SD). These results obtained in systemic vasculitic diseases were consistent with those observed in other studies with cancer patients receiving comparable doses of cyclophosphamide.